{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:48:14Z","timestamp":1790344094099,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIH","award":["HL14285301"],"award-info":[{"award-number":["HL14285301"]}]},{"name":"NIH","award":["HL154103"],"award-info":[{"award-number":["HL154103"]}]},{"name":"NIH","award":["HL14285301"],"award-info":[{"award-number":["HL14285301"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-025-03184-y","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:58:00Z","timestamp":1742295480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Perspective and update: intrapleural fibrinolytic therapy for pleural infections and other forms of pleural organization"],"prefix":"10.1186","volume":"26","author":[{"given":"Torry A.","family":"Tucker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey A.","family":"Komissarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Idell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"3184_CR1","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1012740","volume":"365","author":"NM Rahman","year":"2011","unstructured":"Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, Peckham D, Davies CW, Ali N, Kinnear W, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365:518\u201326.","journal-title":"N Engl J Med"},{"key":"3184_CR2","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/S2213-2600(20)30533-6","volume":"9","author":"U Chaddha","year":"2021","unstructured":"Chaddha U, Agrawal A, Feller-Kopman D, Kaul V, Shojaee S, Maldonado F, Ferguson MK, Blyth KG, Grosu HB, Corcoran JP, et al. Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement. Lancet Respir Med. 2021;9:1050\u201364.","journal-title":"Lancet Respir Med"},{"key":"3184_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.806393","volume":"12","author":"S Karandashova","year":"2021","unstructured":"Karandashova S, Florova G, Idell S, Komissarov AA. From bedside to the bench-a call for novel approaches to prognostic evaluation and treatment of empyema. Front Pharmacol. 2021;12: 806393.","journal-title":"Front Pharmacol"},{"key":"3184_CR4","doi-asserted-by":"publisher","first-page":"L757","DOI":"10.1152\/ajplung.00501.2017","volume":"314","author":"AA Komissarov","year":"2018","unstructured":"Komissarov AA, Rahman N, Lee YCG, Florova G, Shetty S, Idell R, Ikebe M, Das K, Tucker TA, Idell S. Fibrin turnover and pleural organization: bench to bedside. Am J Physiol Lung Cell Mol Physiol. 2018;314:L757\u201368.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"3184_CR5","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/thorax-2023-220304","volume":"78","author":"ME Roberts","year":"2023","unstructured":"Roberts ME, Rahman NM, Maskell NA, Bibby AC, Blyth KG, Corcoran JP, Edey A, Evison M, de Fonseka D, Hallifax R, et al. British thoracic society guideline for pleural disease. Thorax. 2023;78:1143\u201356.","journal-title":"Thorax"},{"key":"3184_CR6","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1513\/AnnalsATS.201609-673OC","volume":"14","author":"N Popowicz","year":"2017","unstructured":"Popowicz N, Bintcliffe O, De Fonseka D, Blyth KG, Smith NA, Piccolo F, Martin G, Wong D, Edey A, Maskell N, Lee YCG. Dose de-escalation of intrapleural tissue plasminogen activator therapy for pleural infection the alteplase dose assessment for pleural infection therapy project. Ann Am Thorac Soc. 2017;14:929\u201336.","journal-title":"Ann Am Thorac Soc"},{"key":"3184_CR7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/resp.14261","volume":"27","author":"N Popowicz","year":"2022","unstructured":"Popowicz N, Ip H, Lau EPM, Piccolo F, Dootson K, Yeoh C, Phu WY, Brown R, West A, Ahmed L, Lee YCG. Alteplase dose assessment for pleural infection therapy (ADAPT) Study-2: use of 25 mg alteplase as a starting intrapleural dose. Respirology. 2022;27:510\u20136.","journal-title":"Respirology"},{"key":"3184_CR8","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.21037\/jtd-21-1083","volume":"13","author":"S Federici","year":"2021","unstructured":"Federici S, Bedat B, Hayau J, Gonzalez M, Triponez F, Krueger T, Karenovics W, Perentes JY. Outcome of parapneumonic empyema managed surgically or by fibrinolysis: a multicenter study. J Thorac Dis. 2021;13:6381\u20139.","journal-title":"J Thorac Dis"},{"key":"3184_CR9","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1164\/rccm.202305-0854OC","volume":"208","author":"EO Bedawi","year":"2023","unstructured":"Bedawi EO, Stavroulias D, Hedley E, Blyth KG, Kirk A, De Fonseka D, Edwards JG, Internullo E, Corcoran JP, Marchbank A, et al. Early video-assisted thoracoscopic surgery or intrapleural enzyme therapy in pleural infection: a feasibility randomized controlled trial the third multicenter intrapleural sepsis Trial-MIST-3. Am J Respir Crit Care Med. 2023;208:1305\u201315.","journal-title":"Am J Respir Crit Care Med"},{"key":"3184_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.7799","volume":"6","author":"CL Wilshire","year":"2023","unstructured":"Wilshire CL, Jackson AS, Vallieres E, Bograd AJ, Louie BE, Aye RW, Farivar AS, White PT, Gilbert CR, Gorden JA. Effect of intrapleural fibrinolytic therapy vs surgery for complicated pleural infections: a randomized clinical trial. JAMA Netw Open. 2023;6: e237799.","journal-title":"JAMA Netw Open"},{"key":"3184_CR11","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(20)31550-6","volume":"396","author":"FM de Benedictis","year":"2020","unstructured":"de Benedictis FM, Kerem E, Chang AB, Colin AA, Zar HJ, Bush A. Complicated pneumonia in children. Lancet. 2020;396:786\u201398.","journal-title":"Lancet"},{"key":"3184_CR12","first-page":"1","volume":"5","author":"L Beckert","year":"2019","unstructured":"Beckert L, Brockway B, Simpson G, Southcott AM, Lee YCG, Rahman N, Light RW, Shoemaker S, Gillies J, Komissarov AA, et al. Phase 1 trial of intrapleural LTI-01; single chain urokinase in complicated parapneumonic effusions or empyema. JCI Insight. 2019;5:1.","journal-title":"JCI Insight"},{"key":"3184_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1164\/rccm.202206-1084OC","volume":"207","author":"EO Bedawi","year":"2023","unstructured":"Bedawi EO, Kanellakis NI, Corcoran JP, Zhao Y, Hassan M, Asciak R, Mercer RM, Sundaralingam A, Addala DN, Miller RF, et al. The biological role of pleural fluid PAI-1 and sonographic septations in pleural infection: analysis of a prospectively collected clinical outcome study. Am J Respir Crit Care Med. 2023;207:731\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"3184_CR14","first-page":"1","volume":"1","author":"DT Arnold","year":"2020","unstructured":"Arnold DT, Hamilton FW, Elvers KT, Frankland SW, Zahan-Evans N, Patole S, Medford A, Bhatnagar R, Maskell NA. Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions. Am J Respir Crit Care Med. 2020;1:1.","journal-title":"Am J Respir Crit Care Med"},{"key":"3184_CR15","first-page":"1","volume":"1","author":"CD Barrett","year":"2024","unstructured":"Barrett CD, Moore PK, Moore EE, Moore HB, Chandler JG, Siddiqui H, Maginot ER, Sauaia A, Perez-Calatayud AA, Buesing K, et al. Neutrophil-mediated inflammatory plasminogen degradation, rather than high plasminogen-activator inhibitor-1, may underly failures and inefficiencies of intrapleural fibrinolysis. Chest. 2024;1:1.","journal-title":"Chest"},{"key":"3184_CR16","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.ajpath.2017.07.007","volume":"187","author":"J Boren","year":"2017","unstructured":"Boren J, Shryock G, Fergis A, Jeffers A, Owens S, Qin W, Koenig KB, Tsukasaki Y, Komatsu S, Ikebe M, et al. Inhibition of glycogen synthase kinase 3beta blocks mesomesenchymal transition and attenuates streptococcus pneumonia-mediated pleural injury in mice. Am J Pathol. 2017;187:2461\u201372.","journal-title":"Am J Pathol"},{"key":"3184_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1165\/rcmb.2018-0121OC","volume":"61","author":"T Tucker","year":"2019","unstructured":"Tucker T, Tsukasaki Y, Sakai T, Mitsuhashi S, Komatsu S, Jeffers A, Idell S, Ikebe M. Myocardin is involved in mesothelial-mesenchymal transition of human pleural mesothelial cells. Am J Respir Cell Mol Biol. 2019;61:86\u201396.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3184_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1165\/rcmb.2023-0131OC","volume":"70","author":"S Keshava","year":"2024","unstructured":"Keshava S, Owens S, Qin W, Jeffers A, Kyei P, Komatsu S, Kleam J, Ikebe M, Idell S, Tucker TA. The mTORC2\/SGK1\/NDRG1 signaling axis is critical for the mesomesenchymal transition of pleural mesothelial cells and the progression of pleural fibrosis. Am J Respir Cell Mol Biol. 2024;70:50\u201362.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3184_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1165\/rcmb.2021-0175OC","volume":"66","author":"G Qian","year":"2022","unstructured":"Qian G, Adeyanju O, Roy S, Sunil C, Jeffers A, Guo X, Ikebe M, Idell S, Tucker TA. DOCK2 promotes pleural fibrosis by modulating mesothelial to mesenchymal transition. Am J Respir Cell Mol Biol. 2022;66:171\u201382.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3184_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms23031587","volume":"23","author":"TA Tucker","year":"2022","unstructured":"Tucker TA, Idell S. Update on novel targeted therapy for pleural organization and fibrosis. Int J Mol Sci. 2022;23:1.","journal-title":"Int J Mol Sci"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03184-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-025-03184-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03184-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:58:05Z","timestamp":1742295485000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-025-03184-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3184"],"URL":"https:\/\/doi.org\/10.1186\/s12931-025-03184-y","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Drs. Tucker and Komissarov declare no COI related to this work and Dr. Idell has a COI Management Plans from the University of Texas at Tyler. Dr. Idell has equity in Aileron Therapeutics Inc., which is commercializing single chain urokinase for pleural loculation and failed drainage in empyema among other products. He founded Lung Therapeutics, Inc which was acquired by Aileron, now called Rein; a publicly traded company. The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"105"}}